Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Next Previous
Search
Trial Profile

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DapKid

    • Most Recent Events

    • 06 Oct 2023 Results of post-hoc analysis assessing the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on extracellular matrix (ECM) remodeling biomarkers, associated with fibrosis, in serum of persons with type 2 diabetes (T2D) and albuminuria. We hypothesized that treatment with dapagliflozin would lower ECM markers in serum compared with placebo, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Aug 2022 Results assessing effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria published in the Diabetes Care
    • 11 Jun 2019 Primary endpoint (Change in Urinary Peptide Patterns (Proteomics)) has been met as per results presented at the 79th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top